Research conducted on obese mouse models has demonstrated that lowering DGAT2 expression through antisense oligonucleotide treatment improves hepatic steatosis, but simultaneously exacerbates the development of liver fibrosis (Schulze and McNiven 2023; 2019). This evidence concerns the gene DGAT2 and fatty liver disease.